🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

RecruitingPhase 2Ages 18 Years - anyAllSaint Petersburg State University, Russia
NCT06374602 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * immunohistochemically verified anaplastic thyroid cancer that is not eligible to R0-R1 surgery; * age ≥ 18 years; * functional status of ECOG 0-2; * adequate function of internal organs and bone marrow; * the ability to give written informed consent. Exclusion Criteria: * patients with a mutation in the BRAF V600 gene without previous targeted therapy with BRAF/MEK inhibitors; * patients with clinically significant hemoptysis and bleeding (for example, from the gastrointestinal tract or tumor-associated bleeding); * tumor invasion into large vessels; * patients with open wounds and fistulas; * contraindications to taking any of the studied drugs; * patients with poor functional status (ECOG 3-4); * continuous use of immunosuppressive therapy; * prior therapy with investigational drugs; * pregnancy, breast-feeding
💊

What it tests

  • Pembrolizumab + Lenvatinib
📍

Where

1 site
Saint Petersburg State University Hospital
Saint Petersburg, Russia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy